AU2003236734A1 - Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles - Google Patents

Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles Download PDF

Info

Publication number
AU2003236734A1
AU2003236734A1 AU2003236734A AU2003236734A AU2003236734A1 AU 2003236734 A1 AU2003236734 A1 AU 2003236734A1 AU 2003236734 A AU2003236734 A AU 2003236734A AU 2003236734 A AU2003236734 A AU 2003236734A AU 2003236734 A1 AU2003236734 A1 AU 2003236734A1
Authority
AU
Australia
Prior art keywords
bleb
meningococcal
strain
bactericidal activity
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003236734A
Other languages
English (en)
Inventor
Ramon Faustino Barbera Morales
Pierre Michel Desmons
Francisco Jesus Dominguez Alvarez
Jan Poolman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
INSTITUTO FINLAY
Original Assignee
GlaxoSmithKline Biologicals SA
INST FINLAY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA, INST FINLAY filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2003236734A1 publication Critical patent/AU2003236734A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003236734A 2002-06-13 2003-06-10 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles Abandoned AU2003236734A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0213622.4 2002-06-13
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation
PCT/EP2003/006094 WO2003105890A2 (en) 2002-06-13 2003-06-10 Vaccine composition

Publications (1)

Publication Number Publication Date
AU2003236734A1 true AU2003236734A1 (en) 2003-12-31

Family

ID=9938532

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003236734A Abandoned AU2003236734A1 (en) 2002-06-13 2003-06-10 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles

Country Status (20)

Country Link
US (1) US20060110412A1 (https=)
EP (1) EP1565211A2 (https=)
JP (1) JP2005531614A (https=)
KR (1) KR20050049431A (https=)
CN (1) CN100387298C (https=)
AR (1) AR040204A1 (https=)
AU (1) AU2003236734A1 (https=)
BR (1) BR0311777A (https=)
CA (1) CA2488782A1 (https=)
CL (1) CL2003001192A1 (https=)
CU (1) CU23552A1 (https=)
GB (1) GB0213622D0 (https=)
MX (1) MXPA04012568A (https=)
NO (1) NO20050132L (https=)
NZ (1) NZ560766A (https=)
PE (1) PE20040562A1 (https=)
RU (1) RU2005100509A (https=)
UY (1) UY27843A1 (https=)
WO (1) WO2003105890A2 (https=)
ZA (1) ZA200409547B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
PL1973564T3 (pl) * 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
US8945582B2 (en) 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
WO2009050586A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS
EP2235531B1 (en) * 2008-02-01 2015-01-14 Sanofi Pasteur Limited Assay for diagnosing streptococcus pneumoniae
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
CN102740882A (zh) 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
JP5860402B2 (ja) * 2009-10-08 2016-02-16 イオン メディックス インコーポレイテッド 室内空気由来細胞外ベシクルを含む組成物及びその用途
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG10201501980SA (en) 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
CN102802664B (zh) * 2009-12-22 2017-04-05 赛诺菲巴斯德有限公司 免疫原性组合物
CN102802662A (zh) 2010-03-18 2012-11-28 诺华有限公司 用于脑膜炎球菌血清组b的含佐剂疫苗
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2011127302A2 (en) * 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
BR112013005626B1 (pt) * 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
JP5957541B2 (ja) 2012-02-02 2016-07-27 ノバルティス アーゲー 髄膜炎菌における増加したタンパク質発現のためのプロモータ
JP2015517089A (ja) 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
MX357538B (es) 2012-06-14 2018-07-13 Novartis Ag Vacunas para meningococo de serogrupo x.
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
US12161707B2 (en) 2016-09-02 2024-12-10 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
AU2021364838A1 (en) * 2020-10-23 2023-06-08 Omvax, Inc. Compositions and methods for vaccination against neisseria gonorrhoeae
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL338146A1 (en) * 1997-07-17 2000-09-25 North American Vaccine Immunogenic complex combinations consisting of meningococcal porine of b group and h. influenzae polysaccharide
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6936261B2 (en) * 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis

Also Published As

Publication number Publication date
CA2488782A1 (en) 2003-12-24
WO2003105890A2 (en) 2003-12-24
AR040204A1 (es) 2005-03-16
CU23552A1 (es) 2010-07-20
RU2005100509A (ru) 2006-06-10
GB0213622D0 (en) 2002-07-24
NO20050132L (no) 2005-02-11
BR0311777A (pt) 2005-03-29
PE20040562A1 (es) 2004-10-19
UY27843A1 (es) 2003-12-31
WO2003105890A3 (en) 2004-03-25
MXPA04012568A (es) 2005-09-21
CN1668329A (zh) 2005-09-14
CN100387298C (zh) 2008-05-14
US20060110412A1 (en) 2006-05-25
CL2003001192A1 (es) 2005-01-07
ZA200409547B (en) 2006-07-26
KR20050049431A (ko) 2005-05-25
NO20050132D0 (no) 2005-01-11
JP2005531614A (ja) 2005-10-20
EP1565211A2 (en) 2005-08-24
NZ560766A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
US20060110412A1 (en) Vaccine composition
TWI360424B (en) Vaccine
JP5275983B2 (ja) ワクチン
US20170209562A1 (en) Immunogenic composition
EP1572729B1 (en) Mutant frpb protein and refolding method

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted